Pasifolate exatecan

N/A

Report date: 2025/12/26 10:28:47
NME

Base Information

Drug NamePasifolate exatecan
Drug Alias NameELU-001EC-112002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitorsFolate receptor alpha modulators
TargetsDNA topoisomerase IFolate receptor alpha
Therapy Area/IndicationsUterine DiseasesOvarian DiseasesNeoplasm Metastasis +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesElucida Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesElucida Oncology Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsUterine DiseasesOvarian DiseasesNeoplasm Metastasis +[10] 

Other Information

ATC CodeN/A
Related LinksN/A